Febuxostat CAS 144060-53-7 Purity >99.0% (HPLC) API Factory

Short Description:

Chemical Name: Febuxostat

CAS: 144060-53-7

Purity: >99.0% (HPLC)

Appearance: White to Off-White Crystalline Powder

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Febuxostat Related Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5

Chemical Properties:

Chemical Name	Febuxostat
Synonyms	2-(3-Cyano-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylic Acid
CAS Number	144060-53-7
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C16H16N2O3S
Molecular Weight	316.38
Melting Point	207.0 to 211.0℃
Density	1.31±0.1 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Crystalline Powder
Identification	HPLC/IR
Purity / Analysis Method	>99.0% (HPLC on dried basis)
Loss on Drying	<1.00% (Dry it at 105℃ in an electric air blowing dryer till a constant weight)
Residues on Ignition	<0.10%
Related Substances
Maximum Single Impurity	<0.30%
Total Impurities	<1.00%
Chlorides	<0.04%
Heavy Metals	<20ppm
Test Standard	Enterprise Standard
Usage	API

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Febuxostat (CAS: 144060-53-7), sold under the brand names Uloric and Adenuric among others, is a medication used long-term to treat gout due to high uric acid levels. It is generally recommended only for people who cannot take allopurinol. When initially started, medications such as NSAIDs are often recommended to prevent gout flares. It is taken by mouth. Febuxostat was approved for medical use in the European Union in 2008 and in the United States in 2009. Febuxostat is used to treat chronic gout and hyperuricemia. Febuxostat is typically recommended only for people who cannot tolerate allopurinol.